90767-54-7

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-Chlorophenyl)pyrimidine-2,4,6(1H,3H,5H)-trione is used as a building block for the development of new drugs and therapeutic agents due to its unique structure and properties. It can be utilized in the synthesis of diverse chemical compounds and drug candidates, contributing to the advancement of pharmaceutical research and development.
Used in Research and Development:
1-(4-Chlorophenyl)pyrimidine-2,4,6(1H,3H,5H)-trione is used as a research tool for studying structure-activity relationships and chemical reactivity. Its distinctive features make it valuable in understanding the interactions and effects of similar compounds, which can lead to the discovery of new drugs and therapeutic agents.

Upstream product

• 105-53-3 diethyl malonate 
• 140-38-5 N-(4-chlorophenyl)urea 

Downstream Products

• 71598-71-5 1-(4-chlorophenyl)-3-(4-chlorophenylsulfonyl)pyrimidine-2,4,6-(1H,3H,5H)-trione 
• 1228963-46-9 1-(4-chlorophenyl)-3-phenylsulfonylpyrimidine-2,4,6-(1H,3H,5H)-trione 
• 53855-73-5 1-(4-chlorophenyl)-3-(4-methylphenylsulfonyl)pyrimidine-2,4,6-(1H,3H,5H)-trione 
• 1455482-93-5 5-benzyl-5-bromo-1-(4-chlorophenyl)pyrimidine-2,4,6-trione 
• 1455482-94-6 5-(4-chlorobenzyl)-5-bromo-1-(4-chlorophenyl)pyrimidine-2,4,6-trione 
• 1455482-99-1 1-(4-chlorophenyl)-5-benzyl-pyrimidine-2,4,6-trione 
• 1455482-95-7 5-(4-chlorobenzyl)-1-(4-chlorophenyl)pyrimidine-2,4,6-trione 
• 330843-66-8 5-(4-chlorobenzylidene)-1-(4-chlorophenyl)pyrimidine-2,4,6-trione 
• 330843-31-7 5-benzylidene-1-(4-chlorophenyl)pyrimidine-2,4,6-trione 

Relevant academic research and scientific papers

Novel Deazaflavin Analogues Potently Inhibited Tyrosyl DNA Phosphodiesterase 2 (TDP2) and Strongly Sensitized Cancer Cells toward Treatment with Topoisomerase II (TOP2) Poison Etoposide

Topoisomerase II (TOP2) poisons as anticancer drugs work by trapping TOP2 cleavage complexes (TOP2cc) to generate DNA damage. Repair of such damage by tyrosyl DNA phosphodiesterase 2 (TDP2) could render cancer cells resistant to TOP2 poisons. Inhibiting TDP2, thus, represents an attractive mechanism-based chemosensitization approach. Currently known TDP2 inhibitors lack cellular potency and/or permeability. We report herein two novel subtypes of the deazaflavin TDP2 inhibitor core. By introducing an additional phenyl ring to the N-10 phenyl ring (subtype 11) or to the N-3 site of the deazaflavin scaffold (subtype 12), we have generated novel analogues with considerably improved biochemical potency and/or permeability. Importantly, many analogues of both subtypes, particularly compounds 11a, 11e, 12a, 12b, and 12h, exhibited much stronger cancer cell sensitizing effect than the best previous analogue 4a toward the treatment with etoposide, suggesting that these analogues could serve as effective cellular probes.

Cyplecksins are covalent inhibitors of the pleckstrin homology domain of cytohesin

The covalent grip: A new class of 5-bromobarbiturates (Cyplecksins; see structure) act by a covalent mechanism to inhibit the biological function of the pleckstrin homology domain of cytohesins, small guanine nucleotide exchange factors for the Ras-like ARF-GTPases. In cells, Cyplecksins interfere with the phosphoinositol-dependent membrane recruitment of cytohesins. Cyplecksins may be useful in validating cytohesins as potential drug targets. Copyright

Synthesis and antitumor evaluation of novel cyclic arylsulfonylureas: ADME-T and pharmacophore prediction

Novel derivatives of 5-(substituted)benzylidene-3-(4-substituted)phenylsulfonylimidazolidine-2,4-diones (3a-r), 1-(4-substituted)phenylsulfonyl-3-(4-substituted)phenylpyrimidine-2,4,6-(1H,3H,5H)-triones (6a-l), and 3-(4-substituted)phenyl-1-(4-substituted)phenylsulfonylquinazoline-2,4(1H,3H)- diones (8a-l) have been synthesized and tested for their antitumor activity against 60 tumor cell lines taken from 9 different organs. The tested compounds have showed good inhibitory effect at the ovarian cancer (IGROV1) cell line. A significant inhibition for (RXF393) renal cancer cells was observed with series 3 compounds, while in the other two series 6 and 8, there was a significant inhibition of ovarian cancer cells (OVCAR-8) and melanoma cells (SK-MEL-2). Interestingly; beside the strong inhibition of compound 3q to IGROV1 and RXF393 cells, a great inhibition (199.62%) for (M14) Melanoma cells was observed at the tested concentration (10?μM). ADME-T and pharmacophore prediction methodology were used to study the antitumor activity of the most active compounds and to identify the structural features required for antitumor activity.

Chemical modification of plant alkaloids. 2. Reaction of cotarnine with barbituric acid derivatives and structure of 5-dihydrocotarnylbarbituric acids

The reaction of barbituric acid and its N-substituted derivatives and 2-thio analogs with cotarnine forms 5-(4-methoxy-6-methyl-5,6,7,8-tetrahydro-2H-1,3-methylenedioxy-[4,5-g]isoquinolinyl-1)barbituric acids, a new class of zwitter-ions, the structure of which was studied by 1H and 13C NMR spectroscopy and mass spectrometry. The prepared compounds exist in solution as stable intermolecular associates and have a complicated H-bonded structure.